We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Earnings Estimates Rising for Aveanna (AVAH): Will It Gain?
Read MoreHide Full Article
Aveanna Healthcare (AVAH - Free Report) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.
Analysts' growing optimism on the earnings prospects of this home health care services provider is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For Aveanna Healthcare, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.
The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:
12 Month EPS
Current-Quarter Estimate Revisions
The earnings estimate of $0.19 per share for the current quarter represents a change of +26.7% from the number reported a year ago.
Over the last 30 days, two estimates have moved higher for Aveanna compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 12.5%.
Current-Year Estimate Revisions
The company is expected to earn $0.80 per share for the full year, which represents a change of +33.3% from the prior-year number.
In terms of estimate revisions, the trend for the current year also appears quite encouraging for Aveanna. Over the past month, three estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 11.11%.
Favorable Zacks Rank
The promising estimate revisions have helped Aveanna earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom Line
Investors have been betting on Aveanna because of its solid estimate revisions, as evident from the stock's 37.4% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away.
View the Zacks #1 Rank List
Image: Bigstock
Earnings Estimates Rising for Aveanna (AVAH): Will It Gain?
Aveanna Healthcare (AVAH - Free Report) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.
Analysts' growing optimism on the earnings prospects of this home health care services provider is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For Aveanna Healthcare, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.
The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:
12 Month EPS
Current-Quarter Estimate Revisions
The earnings estimate of $0.19 per share for the current quarter represents a change of +26.7% from the number reported a year ago.
Over the last 30 days, two estimates have moved higher for Aveanna compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 12.5%.
Current-Year Estimate Revisions
The company is expected to earn $0.80 per share for the full year, which represents a change of +33.3% from the prior-year number.
In terms of estimate revisions, the trend for the current year also appears quite encouraging for Aveanna. Over the past month, three estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 11.11%.
Favorable Zacks Rank
The promising estimate revisions have helped Aveanna earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom Line
Investors have been betting on Aveanna because of its solid estimate revisions, as evident from the stock's 37.4% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away.